About us
Who We Are / Our Philosophy / Our Key Issues
Read More
Research
230+ full scientific papers / 20+ patents / ~40 compounds into formal preclinical research
Read More
Blog
Find out more about our latest news and events
Read More
Précédent
Suivant

Consultancy and Research:
Creation of value by research

Resolution of apparently intractable problems by:

  • Lateral thinking
  • Experimentation
  • Research consortia

Avoid previous mistakes by experience

What we do

We address human “impossible” diseases, pharma, biotech, society and ecology issues

We organise research consortia, symposia, the means to answer key problems

We instill hope and pragmatic solutions

We do research!

We look for collaborations, fundings, novel interactions with many bodies interested in our research and philosophy… This could be you !

What we did

Seven years of the company

  • Established formally as a young innovative company (JEI), eligible for research credits (CIR), with multiple research grants
  • Employed scientists directly in research labs, in multiple collaborations
  • From setting up the company in 2013, we have been involved with 60 Pubmed publications and been listed every year in the Clarivate list of most cited scientists (all disciplines, <150 classed in France)
  • Discovered a new way in for motor neurone disease and identified a patented phase2-ready compound, which has orphan drug designation for ALS, and collaborations in Parkinson’s Disease. This breakthrough has been obtained by a multiple collaborations (see research pages). We are now working on partnership and development.
  • Made a remarkable breakthrough, realising in February 2020 that the enzymes we showed were awry in ALS, are targets for SARS-CoV-2, and can be modified with therapeutic benefit. We are working on clinical trials and setting up major collaborations – we have a major opportunity and are looking to extend our partnerships.
  • Worked on the human limits in performance and ageing showing ageing decline is reflected in a precise single exponential, related toVO2max, with remarkable precision.
  • As Secretary-General of International Union of Pharmacology, IUPHAR, a critical role in world health-care and research. 

Thus we now have the possibility of bringing major therapeutic benefit in ALS and COVID-19

Successful cooperation needs goals, organisation, follow-up and to be win-win. Validation of concepts is via
experimentation, and experimental design is critical. That is one of our strengths.

Publications on Pubmed ‘Spedding M‘

.sciencex_footer { font-size: 10px; }